25th May 2021 15:26
(Alliance News) - Britain's competition watchdog on Tuesday said it was investigating the planned purchase of US biotech company Alexion Pharmaceuticals Inc by Covid-19 vaccine-maker AstraZeneca PLC in a deal worth USD39 billion.
In a brief statement, the Competition & Markets Authority said it was looking at whether the deal would "result in a substantial lessening of competition within any market or markets in the UK for goods or services".
The planned tie-up, aimed at boosting AstraZeneca's work on immunology, was announced in December as the London-listed company began to roll out the coronavirus vaccine it developed with the University of Oxford.
source: AFP
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca